Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Has Consensus Target Price of $6.57 According to Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has received an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $6.57.

NMRA has been the subject of a number of research analyst reports. Weiss Ratings upgraded Neumora Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, September 25th. Royal Bank Of Canada lowered their price target on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Mizuho dropped their price objective on Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a report on Thursday, June 18th. Wall Street Zen downgraded shares of Neumora Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, Needham & Company LLC lowered their target price on shares of Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, June 16th.

Neumora Therapeutics Trading Down 15.3%

Shares of NASDAQ NMRA opened at $0.37 on Wednesday. The company has a debt-to-equity ratio of 1.19, a current ratio of 4.50 and a quick ratio of 4.50. The stock has a market capitalization of $69.56 million, a P/E ratio of -0.30 and a beta of 2.95. Neumora Therapeutics has a 1-year low of $0.37 and a 1-year high of $3.65. The business has a fifty day moving average price of $1.10 and a 200 day moving average price of $1.57.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01. Equities research analysts expect that Neumora Therapeutics will post -0.83 EPS for the current fiscal year.

Insider Activity

In related news, insider Daljit Singh Aurora sold 21,055 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $1.60, for a total value of $33,688.00. Following the completion of the transaction, the insider directly owned 48,750 shares in the company, valued at approximately $78,000. This represents a 30.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last three months, insiders have sold 453,833 shares of company stock worth $701,219. 26.94% of the stock is owned by company insiders.

Hedge Funds Weigh In On Neumora Therapeutics

Several hedge funds have recently bought and sold shares of the company. HBK Sorce Advisory LLC acquired a new stake in Neumora Therapeutics during the 2nd quarter worth approximately $26,000. The Manufacturers Life Insurance Company purchased a new stake in Neumora Therapeutics during the 2nd quarter worth about $44,000. AMG National Trust Bank purchased a new position in shares of Neumora Therapeutics in the 2nd quarter valued at about $74,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Neumora Therapeutics in the 2nd quarter valued at about $130,000. Finally, Bank of America Corp DE acquired a new stake in shares of Neumora Therapeutics during the 2nd quarter worth about $171,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for disorders of the brain. The company combines neuroscience research with data science, including its proprietary MAP platform, to identify patient subgroups, discover potential drug targets and support the development of therapies for neurological and neuropsychiatric conditions.

Neumora’s lead investigational product is navacaprant, an oral, selective kappa opioid receptor antagonist being evaluated for major depressive disorder.